Navigation Links
Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
Date:3/13/2013

SAN DIEGO, March 13, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the fourth quarter and year ended December 31, 2012.

Three months ended December 31, 2012
For the three months ended December 31, 2012, Orexigen reported a net loss of $32.5 million, or $0.41 per share, as compared to a net loss of $4.3 million, or $0.09 per share, for the fourth quarter of 2011.

Total operating expenses for the fourth quarter of 2012 were $33.3 million compared to $5.2 million for the fourth quarter of 2011. This overall increase in operating expenses reflects an increase in research and development expenses associated with the conduct of the Light Study, the Contrave® cardiovascular outcomes trial.

Year ended December 31, 2012
For the year ended December 31, 2012, Orexigen reported a net loss of $90.1 million, or $1.27 per share, as compared to a net loss of $28.1 million, or $0.58 per share, for 2011.

Total operating expenses for 2012 were $93.7 million compared to $32.3 million for 2011. This overall increase in operating expenses reflects an increase in research and development expenses associated with the conduct of the Light Study.

As of December 31, 2012, Orexigen had $78.3 million in cash and cash equivalents and an additional $59.1 million in marketable securities, for a total of $137.4 million. Cash burn for 2013 is projected to be between $70 million and $85 million with total burn dependent on the timing of the Light Study interim analysis and associated pre-launch expenses.

"I am extremely proud of the work our team accomplished in 2012 to expedite enrollment of the Light Study, and our focus is now on 2013 which has the potential to be a pivotal year for Orexigen," said Michael Narachi, CEO of
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... -- Research and Markets  has announced the addition ... & Technologies" report to their offering. ... or you wish to expand your product line, you,ll ... The authors know you want to make effective product ... generate improved revenues and take market share from your ...
(Date:8/22/2014)... 22, 2014   Zacks Equity Research highlights Epizyme (Nasdaq: ... Day and Panera (Nasdaq: PNRA - Free Report ) as ... analysis on Amicus Therapeutics (Nasdaq: FOLD - Free Report ), ... SHPG - Free Report ). Here is a ... the Day : The biotech bull market is ...
(Date:8/22/2014)... DUBLIN , August 22, 2014 ... of Hospital TVs Today Lincor announced general ... Patient Engagement solution that delivers a range of education, ... sets.      (Logo: http://photos.prnewswire.com/prnh/20140822/702945) , ... in defining point of care patient engagement to bedside ...
Breaking Medicine Technology:Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Lincor Unveils Next Generation TV-based Patient Engagement Solution 2
... Medical Imaging (RMI) in Flint announced today that it is ... Breast Magnetic Resonance Imaging (MRI) by the American College of ... the Breast MRI Accreditation Program to recognize imaging ... for Breast MRI. RMI received this new distinction after a ...
... Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today ... trial program for APD597 (JNJ-38431055) under its collaboration with ... APD597 and has notified Arena that it is terminating ... GPR119 agonist intended for the treatment of type 2 ...
Cached Medicine Technology:Exciting Healthcare News for Women of Mid Michigan 2Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes 2Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes 3Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes 4Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes 5
(Date:8/22/2014)... Americans know little about how Ebola is transmitted and harbor ... United States, a new survey shows. About four in ... a major Ebola outbreak in the United States, and one-quarter ... get sick with the deadly virus in the next year, ... However, those opinions don,t match reality, the Harvard researchers ...
(Date:8/22/2014)... Mi40x , the latest guide from ... people how they can use a simple 4-minute trick to ... of weeks has caught the attention of Shane Michaels, prompting ... the most well-known bodybuilders in the industry, and if he ... that in itself is a testament to how effective this ...
(Date:8/22/2014)... 2014 Paying tuition and other related ... coming year for four nurse educators pursuing advanced degrees, ... for Nursing Foundation for Nursing Education . This year’s ... $10,000 more than in 2013, thanks to these named ... Elizabeth Isaac Marcil Endowment Funds, both donated by Kathy ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Mueller Sports ... Plantar Fasciitis, an exciting new product that provides non-drug ... to stay active while you heal. The package includes ... truly a new technology – it is not kinesiology ... FasciaDerm® PFTape™ System for Plantar Fasciitis is ...
(Date:8/22/2014)... NJ. August 22, 2014. A new study ... persons with multiple sclerosis (MS) may be able ... The study was epublished ahead of print on ... Helen Genova, Hali Griswold, Nancy D. Chiaravalloti & ... persons with multiple sclerosis doi: 10.3233/NRE-141113). Self-awareness is ...
Breaking Medicine News(10 mins):Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2
... for most commonly used infection-fighters, , MONDAY, Nov. 2 ... raise the risk for most birth defects, though there ... which is the most commonly used antibiotic during pregnancy, ... widely prescribed antibiotics, were not associated with increased risk ...
... TO CORRESPONDENTS , SILVER SPRING, Md., Nov. 2 ... released a listing of eight recent consumer health information ... can be accessed from the agency,s Web page for ... sign-up for e-mail notices of new consumer updates on ...
... , , Highest Levels of BPA Were Detected in ... Dietary Exposure Could Approach Levels Shown to Cause Harm in Animal ... , YONKERS, N.Y., Nov. 2 Consumer Reports, latest tests ... found that almost all of the 19 name-brand foods tested contain ...
... Infants born to women who received influenza vaccine during ... born to unvaccinated mothers, according to preliminary results of ... Medicine. The team presented the study October 29 at ... of America in Philadelphia. Influenza is a ...
... the 2010 Medicare Physician Fee Schedule will restrict life-saving ... wait times to receive care, and cause life threatening ... serious illnesses. "These short sighted, unfounded and ... to cutting-edge imaging scans, and delay diagnosis of cancers ...
... study finds, , MONDAY, Nov. 2 (HealthDay News) -- ... linked to aggression in young children. , This research, ... of Pediatrics & Adolescent Medicine , found that direct ... viewing in the household were both associated with increased ...
Cached Medicine News:Health News:CDC Study Links 2 Antibiotics to Birth Defects 2Health News:CDC Study Links 2 Antibiotics to Birth Defects 3Health News:CDC Study Links 2 Antibiotics to Birth Defects 4Health News:FDA CONSUMER HEALTH INFORMATION UPDATES: Fraudulent H1N1 flu products, hearing aids, sound amplifiers, tobacco regulation, FDA's international posts, LASIK eye surgery, and FDA MedWatch safety alerts 2Health News:FDA CONSUMER HEALTH INFORMATION UPDATES: Fraudulent H1N1 flu products, hearing aids, sound amplifiers, tobacco regulation, FDA's international posts, LASIK eye surgery, and FDA MedWatch safety alerts 3Health News:Consumer Reports: Tests Find Wide Range of Bisphenol A in Canned Soups, Juice, and More 2Health News:Consumer Reports: Tests Find Wide Range of Bisphenol A in Canned Soups, Juice, and More 3Health News:Consumer Reports: Tests Find Wide Range of Bisphenol A in Canned Soups, Juice, and More 4Health News:Consumer Reports: Tests Find Wide Range of Bisphenol A in Canned Soups, Juice, and More 5Health News:Flu vaccine given to women during pregnancy keeps infants out of the hospital 2Health News:Imaging cuts in Medicare fee schedule: An access catastrophe and danger to patients 2Health News:Imaging cuts in Medicare fee schedule: An access catastrophe and danger to patients 3Health News:TV May Increase Aggression in Toddlers 2Health News:TV May Increase Aggression in Toddlers 3
Reusable shielded cable...
... The STREP A OIA MAX test ... of Group A Strep with a simple, ... minutes. This combination of performance, speed, and ... care while reducing overall costs for diagnosing ...
The GC OIA test is a rapid assay for the diagnosis of gonorrhea. Thermo solved the challenge of developing a specific rapid assay for Neisseria gonorrhea by using the proprietary ribosomal protein, ...
... a high performance assay for the undifferentiated ... with a simple, easy-to-use test that provides ... Assay advantages include superior performance with mucoid ... 14-day viral culture enables you to decrease ...
Medicine Products: